RDGL · XBRL financial data

Vivos financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RDGL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	—	year only	—	—	—	—	—	—
Revenue from contracts with customers	7	0*	5	14	5	5*	27	15	2	25*	36	36
Cost of goods and services sold	0*	9*	6	11	4	10*	36	50	15	28*	44	38
Gross profit	7	(9)*	(2)	3	1	(5)*	(9)	(35)	(13)	(3)*	(8)	(2)
Research and development	81	432*	57	100	67	101*	119	108	68	57*	38	49
General and administrative	31	33*	23	55	65	98*	52	81	73	91*	59	82
Total operating expenses	695	934*	576	525	844	657*	854	640	518	1,093*	537	653
Operating income (loss)	(688)	(943)*	(577)	(522)	(843)	(662)*	(864)	(675)	(531)	(1,096)*	(545)	(655)
Net income (loss)	(668)	(1,076)*	(559)	(503)	(825)	(1,023)*	(835)	(646)	(507)	(1,079)*	(1,185)	(830)
Earnings per share, basic USD per share	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00	0.00
Earnings per share, diluted USD per share	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00	0.00
Weighted average shares, basic thousands of shares	370,542	373,827*	389,406	403,382	418,630	426,987*	448,235	453,511	454,305	454,749*	462,160	490,699
Weighted average shares, diluted thousands of shares	370,542	373,827*	389,406	403,382	418,630	426,987*	448,235	453,511	454,305	454,749*	462,160	490,699

Fiscal quarters (RDGL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,537	1,592	1,371	1,724	1,218	2,213	3,265	2,661	2,202	1,559	2,526	2,336
Accounts receivable	8	7	12	14	5	10	9	13	5	22	8	16
Inventory	—	—	—	—	—	—	21	63	63	57	57	56
Total current assets	1,567	1,610	1,382	1,770	1,244	2,233	3,302	2,776	2,295	1,651	2,599	2,441
Property and equipment, net	—	—	—	—	—	—	—	—	—	103	244	338
Right-of-use asset	—	—	—	—	—	—	—	—	—	111	104	97
Total assets	1,567	1,610	1,382	1,770	1,244	2,233	3,302	2,776	2,295	1,868	2,951	2,880
Total current liabilities	107	245	75	167	49	86	115	96	113	118	172	50
Lease liability, non-current	—	—	—	—	—	—	—	—	—	89	81	74
Total liabilities	107	245	75	167	49	86	115	96	113	207	253	124
Accumulated deficit	(81,375)	(82,451)	(83,009)	(83,513)	(84,338)	(85,361)	(86,196)	(86,841)	(87,349)	(88,427)	(89,612)	(90,442)
Total stockholders' equity	1,459	1,365	1,308	1,603	1,196	2,147	3,186	2,679	2,182	1,661	2,697	2,756
Total liabilities and equity	1,567	1,610	1,382	1,770	1,244	2,233	3,302	2,776	2,295	1,868	2,951	2,880
Common shares outstanding (cover page) thousands of shares	370,995	389,894	401,034	417,564	417,593	453,374	453,512	453,804	454,665	482,688	493,891	494,214

Fiscal quarters (RDGL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(668)	(1,076)*	(559)	(503)	(825)	(1,023)*	(835)	(646)	(507)	(1,079)*	(1,185)	(830)
Net cash from operating activities	(222)*	(463)*	(351)	(355)*	(506)*	(471)*	(455)	(605)*	(458)*	(540)*	(430)	(740)*
Purchases of property and equipment	—	—	—	—	—	—	—	—	—	year only	151	95*
Net cash from investing activities	—	—	—	—	—	—	—	—	—	year only	(151)	(95)*
Proceeds from issuing common stock	—	—	—	—	—	year only	—	—	—	—	—	—
Proceeds from issuing equity	0*	529*	130	709*	0*	—	—	—	—	—	—	—
Net cash from financing activities	10*	519*	130	709*	0*	1,465*	1,508	0*	0*	(1)*	1,548	644*
Net change in cash	(212)*	55*	(221)	354*	(506)*	994*	1,053	(605)*	(458)*	(644)*	967	(190)*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vivos	2,336	36	(740)*	494.2M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Fractyl Health	47,140	not reported	(15,901)*	159.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.